Sycomore Asset Management Invests $4.67 Million in Moderna, Inc. (NASDAQ:MRNA)

Sycomore Asset Management bought a new position in Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent disclosure with the SEC. The firm bought 46,332 shares of the company’s stock, valued at approximately $4,667,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. First Pacific Financial purchased a new stake in shares of Moderna in the 3rd quarter worth about $27,000. Arlington Trust Co LLC lifted its position in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after acquiring an additional 290 shares during the period. GPS Wealth Strategies Group LLC lifted its position in Moderna by 54.1% during the 3rd quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock valued at $53,000 after acquiring an additional 180 shares during the period. Archer Investment Corp lifted its position in Moderna by 71.2% during the 3rd quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after acquiring an additional 222 shares during the period. Finally, Parkside Financial Bank & Trust lifted its position in Moderna by 44.9% during the 3rd quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock valued at $58,000 after acquiring an additional 175 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently issued reports on MRNA. HSBC reissued a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a research report on Monday, February 26th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 target price on shares of Moderna in a report on Thursday, March 28th. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price for the company in a report on Tuesday, January 2nd. Finally, Canaccord Genuity Group lifted their target price on shares of Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a report on Friday, February 23rd. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and an average target price of $126.49.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the sale, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Moderna news, President Stephen Hoge sold 2,388 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the completion of the transaction, the president now directly owns 1,515,898 shares in the company, valued at $143,358,473.86. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO James M. Mock sold 647 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the completion of the transaction, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 109,954 shares of company stock worth $11,533,976. 15.20% of the stock is owned by company insiders.

Moderna Stock Performance

NASDAQ MRNA traded up $0.96 during trading hours on Wednesday, hitting $108.85. 3,408,317 shares of the company’s stock traded hands, compared to its average volume of 4,117,106. The business’s fifty day moving average price is $101.85 and its two-hundred day moving average price is $93.64. The company has a current ratio of 3.42, a quick ratio of 3.36 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $41.68 billion, a P/E ratio of -8.77 and a beta of 1.62. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $142.79.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm’s quarterly revenue was down 44.9% compared to the same quarter last year. During the same period in the previous year, the business posted $3.61 earnings per share. Equities research analysts predict that Moderna, Inc. will post -7.51 EPS for the current year.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.